✨ Free AI Report
Invivyd, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Invivyd, Inc.
Company Research

Invivyd, Inc.: Business Overview, Financials & Competitive Analysis

Invivyd, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Invivyd is positioned as a near-term Phase 3 readout play with VYD2311 topline data expected mid-2026, supported by commercial product revenue and solid cash position. Invivyd reported Q4 2025 PEMGARDA net product revenue of $17.2M (up 25% YoY) with ending cash of $226.7M following >$200M raised in H2 2025. The.

What is Invivyd, Inc.'s industry? Invivyd, Inc. (invivyd.com) operates in Biopharmaceutical - Monoclonal Antibodies & Infectious Diseases. AskCyborg classifies Invivyd, Inc. under Biopharmaceutical - Monoclonal Antibodies & Infectious Diseases in its company registry.

Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company's proprietary INVYMAB platform combines state-of-the-art viral sur...

6/ 10Solid

Cyborg Score thesis

Invivyd is positioned as a near-term Phase 3 readout play with VYD2311 topline data expected mid-2026, supported by commercial...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Monoclonal Antibodies & Infectious Diseases
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Invivyd, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Invivyd, Inc.

AskCyborg analysts argue the bull and bear cases for Invivyd, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Invivyd, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Invivyd, Inc. Overview

Pro stress-test →

Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company's proprietary INVYMAB platform combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering to facilitate rapid generation of new monoclonal antibodies to address evolving viral threats. In March 2024, Invivyd received FDA emergency use authorization for its first monoclonal antibody in a planned series of innovative candidates.

Strategic Profile

Pro stress-test →

Invivyd is a commercial-stage company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from devastating consequences of circulating viral threats. The company is advancing VYD2311 with a Phase 3 trial (DECLARATION) targeting mid-2026 topline data and FDA Fast Track designation, while also developing an RSV candidate (VBY329) and pursuing measles monoclonal antibodies.

Competitive Landscape

Pro stress-test →

One of Invivyd's 6 competitors is Vir Biotechnology, a San Francisco-based company. Invivyd competes in the monoclonal antibody space against established players including Vir, GSK, and emerging biotech firms focused on viral infectious diseases. The company's differentiation rests on its INVYMAB platform enabling rapid serial generation of variant-adapted antibodies and commercial-stage execution with PEMGARDA already generating revenue.

Industry Context

Invivyd, Inc. operates in Biopharmaceutical - Monoclonal Antibodies & Infectious Diseases.

Key facts

Founded: 2020 · Headquarters: Waltham, Massachusetts · Revenue: $17.2M · Market cap: $448M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Invivyd, Inc..

  • Q4 2025 PEMGARDA revenues of $17.2M demonstrate early commercial traction with 25% YoY growth
  • VYD2311 Phase 3 DECLARATION trial initiated with topline data expected mid-2026; granted FDA Fast Track designation
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Initiated DECLARATION Phase 3 trial for VYD2311 with 1,770 planned participants and mid-2026 topline data expected
  • December 2025VYD2311 received FDA Fast Track designation for COVID-19 prevention
  • +2 moreTrack every material event for Invivyd, Inc. as it happens. Explore monitoring →
Get alerted when Invivyd, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Vir BiotechnologyMonoclonal antibodies for viral infectious diseases→GSK (formerly Glaxo SmithKline)Monoclonal antibodies and vaccines for viral diseases→GenmabAntibody-based therapies platform→

Compare Invivyd, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Invivyd, Inc. operates in Biopharmaceutical - Monoclonal Antibodies & Infectious Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Monoclonal Antibodies & Infectious Diseases research →
NEW · MCP server

Ask your AI assistant about Invivyd, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Invivyd, Inc. and its top competitor on Cyborg Score”
“What did Invivyd, Inc. do this quarter?”
“Is Invivyd, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Invivyd, Inc. do?+
Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company's proprietary INVYMAB platform combines state-of-the-art viral sur...
What is Invivyd, Inc.'s Cyborg Score?+
Invivyd, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Invivyd, Inc.'s main competitors?+
Named competitors include Vir Biotechnology, GSK (formerly Glaxo SmithKline), Genmab. The full competitive landscape is in the AskCyborg report.
How can I get the full Invivyd, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Invivyd, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Invivyd, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Monoclonal Antibodies & Infectious Diseases research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Genmab A/S